vs
Side-by-side financial comparison of CF BANKSHARES INC. (CFBK) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $15.7M, roughly 1.5× CF BANKSHARES INC.). CF BANKSHARES INC. runs the higher net margin — 40.0% vs -416.2%, a 456.2% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 12.6%). CF BANKSHARES INC. produced more free cash flow last quarter ($18.2M vs $-69.4M). Over the past eight quarters, CF BANKSHARES INC.'s revenue compounded faster (13.7% CAGR vs -10.8%).
CF Bankshares Inc. is a U.S.-based regional bank holding company operating through its community bank subsidiary. It offers a full suite of personal and commercial banking solutions including deposit products, various loan options, wealth management services and digital banking tools, primarily serving individual consumers and small-to-medium business clients across the U.S. Midwest region.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
CFBK vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.7M | $23.0M |
| Net Profit | $5.7M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | 43.4% | -428.9% |
| Net Margin | 40.0% | -416.2% |
| Revenue YoY | 12.6% | 78.8% |
| Net Profit YoY | 29.9% | 25.7% |
| EPS (diluted) | $0.88 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.7M | $23.0M | ||
| Q3 25 | $15.5M | $13.8M | ||
| Q2 25 | $15.6M | $14.2M | ||
| Q1 25 | $14.1M | $16.6M | ||
| Q4 24 | $14.0M | $12.9M | ||
| Q3 24 | $13.1M | $9.1M | ||
| Q2 24 | $12.6M | $7.0M | ||
| Q1 24 | $12.2M | $28.9M |
| Q4 25 | $5.7M | $-95.8M | ||
| Q3 25 | $2.3M | $-101.3M | ||
| Q2 25 | $5.0M | $-101.3M | ||
| Q1 25 | $4.4M | $-114.3M | ||
| Q4 24 | $4.4M | $-128.9M | ||
| Q3 24 | $4.2M | $-135.7M | ||
| Q2 24 | $1.7M | $-147.0M | ||
| Q1 24 | $3.1M | $-107.4M |
| Q4 25 | 43.4% | -428.9% | ||
| Q3 25 | 17.5% | -808.9% | ||
| Q2 25 | 41.1% | -772.2% | ||
| Q1 25 | 39.5% | -726.6% | ||
| Q4 24 | 36.9% | -1059.9% | ||
| Q3 24 | 40.4% | -1589.0% | ||
| Q2 24 | 15.4% | -1998.6% | ||
| Q1 24 | 30.9% | -394.0% |
| Q4 25 | 40.0% | -416.2% | ||
| Q3 25 | 15.1% | -735.2% | ||
| Q2 25 | 32.3% | -710.8% | ||
| Q1 25 | 31.4% | -687.6% | ||
| Q4 24 | 35.2% | -1001.2% | ||
| Q3 24 | 32.2% | -1489.5% | ||
| Q2 24 | 13.5% | -2112.6% | ||
| Q1 24 | 25.2% | -371.3% |
| Q4 25 | $0.88 | $-0.81 | ||
| Q3 25 | $0.36 | $-0.92 | ||
| Q2 25 | $0.77 | $-0.98 | ||
| Q1 25 | $0.68 | $-1.10 | ||
| Q4 24 | $0.68 | $-1.27 | ||
| Q3 24 | $0.65 | $-1.34 | ||
| Q2 24 | $0.26 | $-1.52 | ||
| Q1 24 | $0.47 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $184.4M | $671.4M |
| Total Assets | $2.1B | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $259.0M | $449.9M | ||
| Q3 25 | $272.4M | $511.0M | ||
| Q2 25 | $275.7M | $459.7M | ||
| Q1 25 | $241.0M | $503.7M | ||
| Q4 24 | $235.3M | $601.5M | ||
| Q3 24 | $233.5M | $658.1M | ||
| Q2 24 | $241.8M | $691.1M | ||
| Q1 24 | $236.9M | $791.3M |
| Q4 25 | $184.4M | $671.4M | ||
| Q3 25 | $179.3M | $748.4M | ||
| Q2 25 | $177.0M | $715.3M | ||
| Q1 25 | $172.7M | $779.9M | ||
| Q4 24 | $168.4M | $872.0M | ||
| Q3 24 | $164.0M | $962.6M | ||
| Q2 24 | $159.6M | $971.1M | ||
| Q1 24 | $158.0M | $1.0B |
| Q4 25 | $2.1B | $842.1M | ||
| Q3 25 | $2.1B | $925.3M | ||
| Q2 25 | $2.1B | $898.9M | ||
| Q1 25 | $2.1B | $986.2M | ||
| Q4 24 | $2.1B | $1.2B | ||
| Q3 24 | $2.1B | $1.2B | ||
| Q2 24 | $2.0B | $1.2B | ||
| Q1 24 | $2.0B | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.7M | $-69.3M |
| Free Cash FlowOCF − Capex | $18.2M | $-69.4M |
| FCF MarginFCF / Revenue | 115.6% | -301.6% |
| Capex IntensityCapex / Revenue | 3.1% | 0.5% |
| Cash ConversionOCF / Net Profit | 3.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $33.4M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.7M | $-69.3M | ||
| Q3 25 | $5.5M | $-76.9M | ||
| Q2 25 | $8.0M | $-99.6M | ||
| Q1 25 | $2.2M | $-148.9M | ||
| Q4 24 | $14.2M | $-85.2M | ||
| Q3 24 | $-1.3M | $-84.8M | ||
| Q2 24 | $4.0M | $-58.2M | ||
| Q1 24 | $-1.2M | $-120.7M |
| Q4 25 | $18.2M | $-69.4M | ||
| Q3 25 | $5.2M | $-76.9M | ||
| Q2 25 | $7.8M | $-99.9M | ||
| Q1 25 | $2.2M | $-149.7M | ||
| Q4 24 | $13.9M | $-86.2M | ||
| Q3 24 | $-1.3M | $-86.1M | ||
| Q2 24 | $4.0M | $-59.2M | ||
| Q1 24 | $-1.2M | $-123.2M |
| Q4 25 | 115.6% | -301.6% | ||
| Q3 25 | 33.6% | -558.2% | ||
| Q2 25 | 50.3% | -701.0% | ||
| Q1 25 | 15.2% | -900.1% | ||
| Q4 24 | 99.6% | -669.4% | ||
| Q3 24 | -9.9% | -945.2% | ||
| Q2 24 | 31.6% | -850.9% | ||
| Q1 24 | -9.5% | -425.7% |
| Q4 25 | 3.1% | 0.5% | ||
| Q3 25 | 1.7% | 0.2% | ||
| Q2 25 | 0.7% | 1.7% | ||
| Q1 25 | 0.4% | 4.4% | ||
| Q4 24 | 1.9% | 7.6% | ||
| Q3 24 | 0.2% | 14.0% | ||
| Q2 24 | 0.1% | 14.5% | ||
| Q1 24 | 0.0% | 8.7% |
| Q4 25 | 3.26× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 3.21× | — | ||
| Q3 24 | -0.30× | — | ||
| Q2 24 | 2.35× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CFBK
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
